Patient-First Treatments
from Start to Finish
Advancements in our long-acting injectables are only made possible by a robust R&D pipeline. This allows us to explore new solutions at virtually every stage of treatment development, from pre-clinical research to phase IV development. Tolmar inspires this research to guide the polymer development process and deliver satisfying patient experiences in the areas of urology, oncology, and endocrinology.
Driven to deliver powerful patient experiences
There’s always room for improvement. We never stick to the status quo so we can identify problems and inefficiencies that others aren’t looking for.
We transformed FENSOLVI® and ELIGARD® treatments from separate dual syringes to a single pre-connected syringe system. This created a more streamlined and comfortable treatment experience for our patients and their physicians.
This agility is impossible without our robust R&D pipeline, keeping us focused on improving therapies from pre-clinical research to phase IV development.
Tolmar’s Pipeline
Tolmar’s R&D focuses on delivering treatments to patients in the following areas: Urology, Oncology, Pediatric Endocrinology, Men’s Health, and more
| Treatments in Development | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Phase 4 |
|---|---|---|---|---|---|
| Oncology (General) | |||||
| TOL 2506 | |||||
| TOL 3022 | Men’s Health | ||||
| TOL 2810 | Uro-Onc, Men’s Health, Ped Endo | ||||
| POC – Proof of Concept |
Research Keeps Us Committed to Patients
Tolmar’s main interest in pursuing research and development opportunities is addressing real patient needs. Our responsibility remains focused on our mission for advanced patient care, ensuring each of our improvements are always focused on patients, not profits.
Explore how Tolmar commits itself to patient-minded treatment and support.